半乳糖凝集素9(GAL9)多克隆抗體
Polyclonal Antibody to Galectin 9 (GAL9)
LGALS9; Ecalectin; Lectin,Galactoside-Binding Soluble 9; Tumor antigen HOM-HD-21
- 編號(hào)PAA309Mu01
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 來源多抗制備
- 宿主兔
- 效價(jià)-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 RPA309Mu01-半乳糖凝集素9(GAL9)重組蛋白
- 緩沖液成份磷酸鹽緩沖液（pH7.4, 含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.）
- 性狀液體
- 濃度500μg/mL
- 且適物種-
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 583 ¥ 1361 ¥ 1944 ¥ 4860 ¥ 19440
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
DAB staining on IHC-P; Sample: Mouse Kidney Tissue; Primary Ab: 20μg/ml Rabbit Anti-Mouse GAL9 Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19)
-
DAB staining on IHC-P;
Sample: Mouse Cerebrum Tissue;
Primary Ab: 20μg/ml Rabbit Anti-Mouse GAL9 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Mouse Lung Tissue;
Primary Ab: 20μg/ml Rabbit Anti-Mouse GAL9 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Mouse Liver Tissue;
Primary Ab: 20μg/ml Rabbit Anti-Mouse GAL9 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Mouse Testis Tissue;
Primary Ab: 20μg/ml Rabbit Anti-Mouse GAL9 Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19)
-
WB圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)GAL9的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別GAL9。
用法
免疫印跡：0.2-2μg/mL;1:250-2500
免疫組織化學(xué)：5-20μg/mL;1:25-100
免疫細(xì)胞化學(xué)：5-20μg/mL;1:25-100
最佳稀釋倍數(shù)最終由用戶決定。
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| APA309Mu02 | 半乳糖凝集素9(GAL9)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA309Mu01 | 半乳糖凝集素9(GAL9)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA309Mu01 | 半乳糖凝集素9(GAL9)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA309Mu02 | 半乳糖凝集素9(GAL9)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA309Mu02 | 半乳糖凝集素9(GAL9)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA309Mu01 | 半乳糖凝集素9(GAL9)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA309Mu71 | 半乳糖凝集素9(GAL9)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEA309Mu | 半乳糖凝集素9(GAL9)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA309Mu | 半乳糖凝集素9(GAL9)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA309Mu | 半乳糖凝集素9(GAL9)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| American Journal of Nephrology | Temporal Increases in Urinary Carboxymethyllysine Correlate with Albuminuria Development in Diabetes [Karger: 328581] |
| Clinical Immunology | Galectin-9 administration ameliorates CVB3 induced myocarditis by promoting the proliferation of regulatory T cells and alternatively activated Th2 cells [ScienceDirect: S1521661611001057] |
| Renal Failure | Rat Renal Interstitial Fibroblasts Affect the Th1/Th2 Profile In Vitro [Pubmed: 22013937] |
| BMC Nephrol | Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease [PubMed: 23339460] |
| Retrovirology | Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection [PubMed: PMC3750478] |
| PLoS One. | Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection [PubMed: PMC3480425] |
| PLoS Pathogens | Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C [PubMed: PMC3688567] |
| PLOS ONE | Graves’ Disease Is Associated with a Defective Expression of the Immune Regulatory Molecule Galectin-9 in Antigen-Presenting Dendritic Cells [PubMed: 25880730] |
| Advances in Experimental?Medicine?and?Biology | Molecules of Damage-Associated Patterns in Bronchoalveolar Lavage Fluid and Serum in Chronic Obstructive Pulmonary Disease [Pubmed:29429028] |
| Journal?of?Microbiology,?Immunology?and?Infection | Galectin-9-like from Angiostrongylus cantonensis young adult worms modulates eosinophil chemotaxis in vitro [Doi: 10.1016/j.jmii.2018.09.010] |
| Oncology?Letters | The effects of Tim?3 activation on T?cells in gastric cancer progression [] |
| Scientific Reports | Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra?… [Pubmed: 31337865] |
| Biomolecules | Blood Levels of Galectin-9, an Immuno-Regulating Molecule, Reflects the Severity for the Acute and Chronic Infectious Diseases. Biomolecules 2021, 11, 430 [33804076] |
| Medicine | Regulatory T cells, damage-associated molecular patterns, and myeloid-derived suppressor cells in bronchoalveolar lavage fluid interlinked with chronic obstructive?… [Pubmed:35687771] |
